• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 4, 2017

View Archived Issues

Cullinan secures $150M to build oncology portfolio from ‘diamonds in the rough’

In January 1905, the world’s largest gem-quality rough diamond was discovered at the Premier No. 2 mine in Cullinan, modern-day South Africa, and cut into several polished gemstones, some of which became part of Great Britain’s Crown Jewels. Cullinan Oncology LLC hopes to imitate that feat by building a portfolio of oncology assets from one-off opportunities whose profile makes them unsuitable for single-asset companies. Read More

Recursion lands $60M series B to fund AI-driven drug repurposing, pipeline development

Recursion Pharmaceuticals Inc., a biotech company leveraging artificial intelligence to discover new therapies, has raised a $60 million series B financing led by the Silicon Valley-based venture firm Data Collective. Read More

Stem cell-derived EPO-producing cells can ameliorate renal anemia

Erythropoietin (EPO)-producing cells derived from human induced pluripotent stem (iPS) cells have been shown for the first time to be capable of successfully treating renal anemia in mice, Japanese researchers reported in the Sept. 27, 2017, edition of Science Translational Medicine. Read More

Is right-to-try social justice or loophole for snake oil salesmen?

Potentially a solution seeking a problem, two right-to-try bills considered by a House subcommittee Tuesday could result in more of the unintended consequences that are often a byproduct of U.S. congressional action. Read More

Liver drug with liver toxicity? Not the best combination

It was a rough couple of weeks for Intercept Pharmaceuticals Inc. Read More

Biocardia presses on with Cardiamp pivotal trial to treat HF patients

Biocardia Inc. said an independent data safety monitoring board has found there are no safety concerns for the first 10 patients treated in the phase III Cardiamp cell therapy trial. The San Carlos, Calif.-based company’s ongoing multicenter, double-blind, randomized, sham-controlled trial is expected to enroll 260 patients at up to 40 centers across the U.S. and will continue as planned. Read More

Financings

Ritter Pharmaceuticals Inc., of Los Angeles, said it closed its public offering with total gross proceeds of about $23 million. Read More

Other news to note

Mabvax Therapeutics Holdings Inc., of San Diego, reported that results from studies of its HuMab-5B1 and HuMab-GD2 antibody programs provide additional evidence of the targeting specificity, affinity and potential utility of the candidates. Read More

Appointments and advancements

Durect Corp., of Cupertino, Calif., appointed Myriam Theeuwes senior vice president, clinical development. Read More

In the clinic

Vical Inc., of San Diego, said the FDA deemed its investigational antifungal, VL-2397, would be eligible for a limited use indication (LUI) approval, assuming a successful outcome of a single phase II trial carried out in accordance with a protocol and statistical analysis plan consistent with the agency’s advice. Read More

Regulatory front

The U.S. Centers for Medicare & Medicaid Services (CMS) is withdrawing a proposed Medicare reimbursement model for drugs administered in doctor’s offices and hospitals. Intended to be budget neutral, the controversial model was proposed last year with no input from stakeholders. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe